Insights on the Rapid Acting Insulin Global Market to 2027 - by Product Type, Indication, Distribution Channel and Regional Outlook
July 22, 2021 07:38 ET
|
Research and Markets
Dublin, July 22, 2021 (GLOBE NEWSWIRE) -- The "Global Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast,...
Adocia在1型糖尿病患者中启动BC LisPram通过泵给药的1期临床试验
June 29, 2021 12:00 ET
|
Adocia SA
首次在单个泵中测试与血糖控制相关的两个关键激素，即速效胰岛素类似物和淀粉类似物的独特组合，BioChaperone® 赖脯胰岛素和普兰林肽联合制剂的安全性、药代动力学和血糖控制能力将与赖脯胰岛素进行比较 里昂, June 30, 2021 (GLOBE NEWSWIRE) -- Adocia (巴黎泛欧交易所: FR0011184241 – ADOC),...
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
June 29, 2021 12:00 ET
|
Adocia SA
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域
May 26, 2021 01:30 ET
|
Adocia SA
已申请三项专利系列涵盖新型激素组合：普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权，使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病，例如NASH（非酒精性脂肪性肝炎），2型糖尿病或神经退行性疾病 里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
May 26, 2021 01:30 ET
|
Adocia SA
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...
Global Metabolic Disorders Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery
May 17, 2021 04:58 ET
|
Research and Markets
Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering....